Operating Income (Loss) in USD of Galera Therapeutics, Inc. from Q3 2018 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Galera Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and change rate from Q3 2018 to Q3 2025.
  • Galera Therapeutics, Inc. Operating Income (Loss) for the quarter ending 30 Sep 2025 was -$1.44M, a 75.7% increase year-over-year.
  • Galera Therapeutics, Inc. Operating Income (Loss) for the twelve months ending 30 Sep 2025 was -$10M, a 49.7% increase year-over-year.
  • Galera Therapeutics, Inc. annual Operating Income (Loss) for 2024 was -$20.2M, a 59.1% increase from 2023.
  • Galera Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$49.3M, a 3.84% increase from 2022.
  • Galera Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$51.2M, a 30.2% increase from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Change (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Change (%)

Galera Therapeutics, Inc. Quarterly Operating Income (Loss) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$10M -$1.44M +$4.47M +75.7% 01 Jul 2025 30 Sep 2025 10-Q 13 Nov 2025
Q2 2025 -$14.5M -$1.14M +$3.07M +73% 01 Apr 2025 30 Jun 2025 10-Q 13 Aug 2025
Q1 2025 -$17.5M -$1.96M +$2.61M +57.1% 01 Jan 2025 31 Mar 2025 10-Q 15 May 2025
Q4 2024 -$20.2M -$5.47M -$290K -5.6% 01 Oct 2024 31 Dec 2024 10-K 31 Mar 2025
Q3 2024 -$19.9M -$5.91M +$7.49M +55.9% 01 Jul 2024 30 Sep 2024 10-Q 13 Nov 2025
Q2 2024 -$27.4M -$4.21M +$12.6M +75% 01 Apr 2024 30 Jun 2024 10-Q 13 Aug 2025
Q1 2024 -$40M -$4.58M +$9.3M +67% 01 Jan 2024 31 Mar 2024 10-Q 15 May 2025
Q4 2023 -$49.3M -$5.18M +$8.01M +60.7% 01 Oct 2023 31 Dec 2023 10-K 31 Mar 2025
Q3 2023 -$57.3M -$13.4M -$438K -3.38% 01 Jul 2023 30 Sep 2023 10-Q 13 Dec 2024
Q2 2023 -$56.8M -$16.8M -$4.88M -40.9% 01 Apr 2023 30 Jun 2023 10-Q 14 Aug 2024
Q1 2023 -$52M -$13.9M -$727K -5.53% 01 Jan 2023 31 Mar 2023 10-Q 13 May 2024
Q4 2022 -$51.2M -$13.2M +$1.31M +9.06% 01 Oct 2022 31 Dec 2022 10-K 28 Mar 2024
Q3 2022 -$52.5M -$13M +$7.34M +36.2% 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023
Q2 2022 -$59.9M -$11.9M +$9.16M +43.4% 01 Apr 2022 30 Jun 2022 10-Q 14 Aug 2023
Q1 2022 -$69M -$13.2M +$4.33M +24.8% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023
Q4 2021 -$73.4M -$14.5M +$4.45M +23.5% 01 Oct 2021 31 Dec 2021 10-K 08 Mar 2023
Q3 2021 -$77.8M -$20.3M -$4.22M -26.3% 01 Jul 2021 30 Sep 2021 10-Q 09 Nov 2022
Q2 2021 -$73.6M -$21.1M -$3.38M -19.1% 01 Apr 2021 30 Jun 2021 10-Q 09 Aug 2022
Q1 2021 -$70.2M -$17.5M +$337K +1.89% 01 Jan 2021 31 Mar 2021 10-Q 16 May 2022
Q4 2020 -$70.6M -$18.9M -$2.78M -17.2% 01 Oct 2020 31 Dec 2020 10-K 10 Mar 2022
Q3 2020 -$67.8M -$16.1M -$3.22M -25.1% 01 Jul 2020 30 Sep 2020 10-Q 10 Nov 2021
Q2 2020 -$64.6M -$17.7M -$6.44M -57.2% 01 Apr 2020 30 Jun 2020 10-Q 10 Aug 2021
Q1 2020 -$58.1M -$17.8M -$7.42M -71.4% 01 Jan 2020 31 Mar 2020 10-Q 11 May 2021
Q4 2019 -$50.7M -$16.2M 01 Oct 2019 31 Dec 2019 10-K 11 Mar 2021
Q3 2019 -$12.9M -$7.45M -138% 01 Jul 2019 30 Sep 2019 10-Q 10 Nov 2020
Q2 2019 -$11.3M 01 Apr 2019 30 Jun 2019 10-Q 10 Aug 2020
Q1 2019 -$10.4M 01 Jan 2019 31 Mar 2019 10-Q 12 May 2020
Q3 2018 -$5.41M 01 Jul 2018 30 Sep 2018 10-Q 10 Dec 2019

Galera Therapeutics, Inc. Annual Operating Income (Loss) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$20.2M +$29.1M +59.1% 01 Jan 2024 31 Dec 2024 10-K 31 Mar 2025
2023 -$49.3M +$1.97M +3.84% 01 Jan 2023 31 Dec 2023 10-K 31 Mar 2025
2022 -$51.2M +$22.1M +30.2% 01 Jan 2022 31 Dec 2022 10-K 28 Mar 2024
2021 -$73.4M -$2.82M -3.99% 01 Jan 2021 31 Dec 2021 10-K 08 Mar 2023
2020 -$70.6M -$19.9M -39.2% 01 Jan 2020 31 Dec 2020 10-K 10 Mar 2022
2019 -$50.7M -$26.4M -109% 01 Jan 2019 31 Dec 2019 10-K 11 Mar 2021
2018 -$24.3M 01 Jan 2018 31 Dec 2018 10-K 10 Mar 2020
* An asterisk sign (*) next to the value indicates that the value is likely invalid.